Just reported
From Kenvue's results release of 2026年10月30日; its quarterly report has since been filed.
Actual
US$3.89B
+3.2% y/y
-1.7% q/q
Guided
—
No guide given
Actual
US$0.22
+4.8% y/y
-8.3% q/q
Guided
—
No guide given
Actual
US$706M
+12% y/y
+1.0% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →The themes Kenvue is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
各项收入占比是对quarter ended 2026-09-27的估算,并非来自已提交报告的数字。
Tylenol
Nonprescription medicines for pain and fever.
Zyrtec
Medicines for allergy symptoms.
Nicorette
Products to help people stop smoking.
Neutrogena
Skin and hair care products, including face and body care.
Listerine
Mouthwash and other oral care products.
BAND-AID Brand
Adhesive bandages and other wound-care products.
Its brands include Tylenol and Zyrtec medicines, Neutrogena skin and hair care, Listerine mouthwash, and BAND-AID wound-care products. It sells through retail and online channels around the world. Kenvue has a pending agreement to combine with Kimberly-Clark, subject to remaining conditions and regulatory approvals.
基于 Kenvue Inc. 自己向美国证券交易委员会(SEC)提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
US$19.31-1.3%10月30日 收盘
数据截至2026年9月27日,来自2026年10月30日提交的10-Q
Kenvue sells nonprescription medicines to shoppers through pharmacies and retailers, alongside skin care, mouthwash, baby care and wound-care products.
Grade C+
价格下方的色带显示每个日期的评级,仅依据当时已公开的文件计算。
显示 Kenvue Inc. 评级历史 12 个季度中的 2 个。 其余 10 个可回溯到 2024年3月。